Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5-Lipoxygenase Activating Protein Inhibitor.
Ericsson H, Nelander K, Lagerstrom-Fermer M, Balendran C, Bhat M, Chialda L, Gan LM, Heijer M, Kjaer M, Lambert J, Lindstedt EL, Forsberg GB, Whatling C, Skrtic S. Ericsson H, et al. Among authors: balendran c. Clin Transl Sci. 2018 May;11(3):330-338. doi: 10.1111/cts.12546. Epub 2018 Mar 8. Clin Transl Sci. 2018. PMID: 29517132 Free PMC article. Clinical Trial.
Prothrombin time is predictive of low plasma prothrombin concentration and clinical outcome in patients with trauma hemorrhage: analyses of prospective observational cohort studies.
Balendran CA, Lövgren A, Hansson KM, Nelander K, Olsson M, Johansson KJ, Brohi K, Fries D, Berggren A. Balendran CA, et al. Scand J Trauma Resusc Emerg Med. 2017 Mar 14;25(1):30. doi: 10.1186/s13049-016-0332-2. Scand J Trauma Resusc Emerg Med. 2017. PMID: 28292321 Free PMC article.
Identification of the human ApoAV gene as a novel RORalpha target gene.
Lind U, Nilsson T, McPheat J, Strömstedt PE, Bamberg K, Balendran C, Kang D. Lind U, et al. Among authors: balendran c. Biochem Biophys Res Commun. 2005 Apr 29;330(1):233-41. doi: 10.1016/j.bbrc.2005.02.151. Biochem Biophys Res Commun. 2005. PMID: 15781255
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
Alkhouri N, Herring R, Kabler H, Kayali Z, Hassanein T, Kohli A, Huss RS, Zhu Y, Billin AN, Damgaard LH, Buchholtz K, Kjær MS, Balendran C, Myers RP, Loomba R, Noureddin M. Alkhouri N, et al. Among authors: balendran c. J Hepatol. 2022 Sep;77(3):607-618. doi: 10.1016/j.jhep.2022.04.003. Epub 2022 Apr 16. J Hepatol. 2022. PMID: 35439567 Free article. Clinical Trial.